Research programme: PAR-2 modulator - Peptron
Latest Information Update: 11 Feb 2014
At a glance
- Originator Peptron
- Class Peptidomimetics
- Mechanism of Action PAR 2 receptor antagonists; PAR-2 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation
Most Recent Events
- 11 Feb 2014 Early research in Inflammation in South Korea